

Product Information

Anti-Human Kappa Light Chain (Bound and Free) antibody produced in goat

Catalog Number **K3502**

Product Description

Antiserum is developed in goat using purified human normal and myeloma kappa light chain as the immunogen. Affinity isolated antigen specific antibody is obtained by immunospecific purification to remove essentially all goat serum proteins, including immunoglobulins, which do not specifically bind to human kappa light chains (bound and free). The antibody preparation is lyophilized from 0.01 M sodium phosphate with 0.015 M sodium chloride, pH 7.2, to which no preservatives have been added.

Specificity for the kappa chain of human immunoglobulins is determined by immunoelectrophoresis (IEP) and ELISA. Reactivity against a 5 mg/ml coat of Human IgG1*, Human IgA1, and Human IgM1 must be <10% of the reactivity to Human IgGk*, Human IgAk, and Human IgMk, respectively. Reactivity against a 200 ng/ml coat of Human Bence Jones Lambda must be <10% of the reactivity to a 200 ng/ml coat of Human Bence Jones Kappa.

*Any subclass is acceptable.

Identity and purity of the antibody is established by immunoelectrophoresis. Electrophoresis of the antibody preparation followed by diffusion versus anti-goat IgG and anti-goat whole serum results in single arcs of precipitation.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

To one vial of lyophilized powder, add sufficient 0.135 M sodium chloride to achieve a 1 mg/ml solution of antibody. Rotate vial gently until powder dissolves. This will yield a protein solution in 0.01 M phosphate buffered saline.

Storage/Stability

Prior to reconstitution store the product at 2–8 °C. After reconstitution, the solution may be stored frozen in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage clarify the solution by centrifugation before use.

Reference

1. Becker, W., Immunochem, **6**, 539, (1969).

TT,PCS,MAM 11/18-1